Quick Facts

• Relief of Inflammation: Addresses inflammation of the nasal passages.
• Symptom Management: Helps manage nasal symptoms associated with certain infections.
• Used for: Acute rhinosinusitis and inflammatory conditions of the nose.

---

What Полидекса Treats: Main Uses and Benefits

Полидекса is a combination product typically prescribed to address inflammatory conditions of the nasal passages and certain ear infections. The nasal formulation, often containing neomycin, polymyxin B, dexamethasone, and phenylephrine, is indicated for the symptomatic management of acute rhinosinusitis. The combination of ingredients contributes to a reduction in local inflammation and swelling within the nasal tissues, which helps to facilitate breathing.

In the context of ear use, formulations containing neomycin, polymyxin B, and a corticosteroid (like dexamethasone or hydrocortisone) are indicated for superficial bacterial infections of the external auditory canal, and to address associated redness and discomfort. These components work to support the body in clearing susceptible bacterial infections and managing the inflammatory response that may accompany them. It is important that this medication be used exactly as directed by a healthcare professional.

---

Regulatory References

1. DailyMed Prescribing Information

Who can and cannot use Полидекса

Eligibility to use the combination medicine Полидекса (Neomycin, Polymyxin B, Dexamethasone) is strictly defined by regulatory criteria, focusing on patient status and the nature of the underlying condition.

---

Absolute Contraindications

Use of this medicine is prohibited for patients with a known hypersensitivity to Dexamethasone, Neomycin, Polymyxin B, or any inactive ingredient. It is also contraindicated when the infection at the site of administration is confirmed to be viral (such as Herpes Simplex), fungal, or mycobacterial. For the otic (ear) preparation, use is strictly forbidden if the patient has a perforated tympanic membrane (eardrum).

---

Age and Conditional Use

The medicine is established for use in adults and older adults. For pediatric patients, use is generally allowed for children 2 years of age and older. However, safety and efficacy have not been established in children younger than 2 years of age. Use during pregnancy and lactation is classified as conditional, requiring caution and medical determination that the potential benefit outweighs the potential risk. No explicit restrictions are noted for systemic hepatic or renal impairment for the topical solution.

Interactions with other medicines and products

The potential for drug-drug interactions with Poly-Dex (dexamethasone, neomycin, and polymyxin B) is primarily related to the systemic absorption of its components, particularly the corticosteroid dexamethasone.

Pharmacokinetic Interactions

Dexamethasone is metabolized by the enzyme Cytochrome P450 3A4 (CYP3A4). Concomitant use with strong inhibitors of this enzyme can reduce the clearance of dexamethasone, potentially increasing its systemic concentration and the risk of related adverse effects, such as adrenal suppression. For this reason, co-administration with strong CYP3A4 inhibitors, including Ritonavir and Cobicistat, is generally not recommended or contraindicated unless the benefit outweighs the increased systemic risk, and the patient is closely monitored.

Pharmacodynamic and Procedural Interactions

Category	Interaction Concern	Constraint/Condition
Other Topical Steroids	Increased risk of systemic side effects (e.g., Cushing's syndrome, adrenal suppression) due to cumulative absorption.	Use with caution; monitor for systemic effects.
Other Aminoglycosides	Increased risk of ototoxicity or nephrotoxicity from cumulative systemic absorption.	Use with caution; monitor for systemic effects.
Multiple Ophthalmic Products	Interference with proper absorption and efficacy of the drops/ointments.	Administer other topical eye products at least 5 minutes apart.

It is essential to inform a healthcare professional about all other prescription and non-prescription medicines, vitamins, and herbal supplements being used.

The mechanism of action of Полидекса is derived from the concurrent, spatially-focused activity of its three primary pharmacological agents: neomycin sulfate, polymyxin B sulfate, and dexamethasone.

Neomycin, an aminoglycoside antibiotic, selectively penetrates the bacterial cell wall and binds irreversibly to the 30S ribosomal subunit. This interaction destabilizes the translational machinery, inducing misreading of the mRNA template and inhibiting peptide chain elongation, which results in the production of aberrant, non-functional proteins, leading to bacterial cell demise.

Polymyxin B, a lipopeptide antibiotic, targets the outer and inner cell membranes of Gram-negative bacteria. It interacts electrostatically with the negatively charged lipopolysaccharide (LPS) and phospholipid components, displacing stabilizing divalent cations like Ca^2+ and Mg^2+. This detergent-like action structurally compromises the membrane, increasing permeability and causing leakage of cytoplasmic contents, leading to bactericidal effect.

Dexamethasone, a synthetic glucocorticoid, acts as an agonist for the intracellular glucocorticoid receptor (GR). Upon ligand binding, the activated GR translocates to the nucleus, where it functions as a transcription factor, binding to glucocorticoid response elements (GREs) to modulate the transcription of target genes. Downstream, this genomic pathway mediates the transrepression of pro-inflammatory transcription factors like NF-kappaB and AP-1, resulting in the diminished synthesis and release of inflammatory mediators, including cytokines (e.g., IL-1, TNF-alpha) and chemokines. This cascade leads to reduced local vascular permeability and decreased migration of immune cells to the targeted tissue site.

Administration Guidelines for Полидекса Nasal Spray

Полидекса with Phenylephrine is an intranasal spray, and its use is governed by age-specific dosing and duration limits.

Administration and Dosing:

Age Group	Dose per Nostril	Frequency	Maximum Duration
Adults	1 spray	3 to 5 times per day	10 days
Children (2.5 to 18 years)	1 spray	3 times per day	10 days

Procedural Steps

1. Route and Technique: The medicine must be administered locally intranasally (into the nose). For proper application, the bottle should be held in a vertical position with the sprayer pointed upward.
2. Duration Limit: The total duration of treatment is strictly limited and must not exceed 5 to 10 days.
3. Forbidden Use: The preparation is prohibited from being used for the washing of the paranasal sinuses (irrigation).
4. Missed Dose: Documentation for this preparation does not explicitly describe a rule for handling a missed dose.

---

Research Evidence / Overview of Studies for Полидекса

---

Evidence for Topical Use in Acute Otitis Externa

This section will summarize the type and quality of research, including Randomized Controlled Trials (RCTs) and meta-analyses, that examine the combination agent in research settings for superficial bacterial infections of the external ear canal.

The combination of ingredients found in Poliдекса was studied for conditions associated with acute or disruptive episodes, specifically Acute Otitis Externa (AOE). Studies examined outcomes related to physical discomfort, monitoring the evolution of clinical resolution rates and microbiologic eradication rates in the observed populations. Research also explored changes in symptoms like pain, swelling, and ear discharge over defined time intervals.

The evidence level for this topical combination is broadly assigned the grade of High by major reviewers. Studies monitored patient responses over short-term observation periods, typically around 10 to 18 days following the start of treatment. Findings describe patterns observed in these studies regarding clinical resolution and how symptoms evolved during the study period.

---

Evidence for Nasal Use in Acute Rhinosinusitis

This section will outline the structure of the clinical data, including comparative clinical studies, that researched this formulation for localized infecto-inflammatory conditions of the nose and paranasal sinuses.

This formulation was studied for its use in conditions associated with acute or disruptive episodes, specifically acute rhinosinusitis. Research was conducted using short-term comparative clinical studies that primarily included adults with moderate nasal and sinus inflammation. Researchers explored how symptoms are measured, focusing on outcomes related to inflammatory or irritative states, such as changes in patient-reported complaints and the function of the sense of smell.

---

The Overall Strength and Gaps in the Evidence

The evidence level varies depending on the indication: the research examining Acute Otitis Externa is assigned the grade of High by reviewers, while the nasal formulation is assigned the grade of Moderate.

Across both indications, there are clear research gaps. Sample sizes were modest in the nasal studies, meaning the results apply only to the populations studied. Research highlights what is known—and what is still uncertain—particularly where long-term effects are not fully established and follow-up durations were limited.

Key Studies & References DailyMed Prescribing Information for Neomycin and Polymyxin B Sulfates and Dexamethasone Otic Solution

Common questions about Полидекса (FAQ)

Q: What types of infections is Полидекса generally used for?

Official product information describes Poliideksa as used for the topical management of certain forms of otitis (ear infection) and bacterial infections affecting the ear or nose. The medicine is classified as a combined anti-inflammatory and antimicrobial agent, which helps address both the microbial component and the resulting irritation.

Q: Is Полидекса considered an antibiotic?

Poliideksa is officially classified as a combined anti-inflammatory and antimicrobial agent, meaning its purpose is to address both inflammation and the microbial cause. It contains two specific antibiotics, Neomycin and Polymyxin B, alongside the corticosteroid Dexamethasone, to target a range of susceptible bacteria.

Q: What are the most commonly reported side effects of Полидекса?

According to official regulatory documents, the most commonly reported side effects involve reactions at the application site. Patients may experience a stinging or burning sensation in the ears or eyes after using the drops. Regulatory guidance encourages patients to seek medical guidance if side effects are severe or persistent.

Q: Is Полидекса considered safe for children?

Official guidance establishes the use of Poliideksa for children aged 2 years and older. For any pediatric patient, the dose and duration of use are strictly determined by a physician based on the child's age and condition. Adherence to the specific instructions provided by the healthcare provider is required by the product label.

Q: What should be done if an allergic reaction is suspected after using Полидекса?

Regulatory instructions indicate the importance of informing a physician immediately if any severe side effects or adverse reactions are suspected. Medical assessment should be sought as guided by a healthcare professional.

Q: Does Poliideksa contain vasoconstrictors?

Poliideksa is available in a formulation intended for nasal use that contains the vasoconstrictor Phenylephrine; this product is specifically named Poliideksa with Phenylephrine. Due to the difference in product formulations, patients are directed to refer to the official package label for the specific version prescribed.

Q: What is the typical timeframe for improvement when using Полидекса?

Official guidance states that clinical expectations regarding the timeframe for noticing an effect are determined by the treating physician based on the individual condition and response to the medication. This determination also governs the appropriate treatment timeframe.

Q: Is it acceptable to use Полидекса while driving?

The official label includes a warning stating that patients should avoid driving or operating heavy machinery immediately after administration due to the potential for temporary blurring of vision. The label suggests waiting until vision is completely clear before resuming these activities.

Q: Is Полидекса known to cause drowsiness?

The official safety statement regarding operating machinery concerns the potential for temporary blurring of vision. Although drowsiness is not the effect noted in regulatory documents, regulatory guidance instructs patients to refrain from operating machinery if their vision is not completely clear.

Q: Can the components of Полидекса be absorbed into the bloodstream?

Although Poliideksa is a topical solution, regulatory labeling includes warnings about the risk of rare systemic effects, such as Cushing’s syndrome or adrenal suppression, with prolonged or high-dose use. This indicates that some level of systemic absorption of the corticosteroid component is possible.

Q: Is it necessary to shake the bottle before using Полидекса?

Official directions for the otic solution or suspension require the bottle to be shaken well before use. This procedure is intended to ensure that the active components are evenly distributed throughout the medication prior to application.

Q: Does the efficacy of Полидекса decrease after the bottle is opened?

Regulatory guidelines address the stability of the product after opening. Official quick tips state that the open bottle should not be used for more than four weeks to maintain product quality and efficacy.

Q: Are there any known interactions between Полидекса and alcohol?

According to the official regulatory information for Poliideksa, no interaction has been found or established between this medication and alcohol.

Q: Can Полидекса be used after its expiration date?

Official instructions require that the bottle be disposed of at the end of the full course of treatment, and any residue must not be stored for re-use. This regulatory guidance effectively prohibits the use of the medication beyond the prescribed course or its expiration date.

How to Store and Dispose of Polydexa

The storage and disposal of Polydexa drops must follow the official requirements stated in regulatory documentation to maintain product stability and safety.

Storage Conditions

The medicine should be stored at a controlled room temperature, generally between 15°C and 25°C. It is mandatory to keep the medicine from freezing and to protect it from excessive heat, moisture, and direct light. The product must be kept in its original container with the lid tightly closed when not in use. Always store Polydexa out of the sight and reach of children.

Disposal Instructions

Unused or expired drops must not be kept. The safest method of disposal is utilizing a drug take-back program. If a take-back program is unavailable, the product should be mixed with an unappealing substance (like dirt or coffee grounds), sealed in a container, and placed in the household trash. Do not flush the product down the toilet or pour it down a sink.